Gerald Behr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gerald Behr has a total of 385 co-authors. Here are the top co-authors by number of shared publications:
- Neeta Pandit-Taskar
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
6 shared publications - Alexander J. Towbin
Department of Radiology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA
4 shared publications - Paul A. Meyers
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
4 shared publications Ajaykumar C. Morani
Division of Diagnostic Imaging The University of Texas MD Anderson Cancer Center Houston Texas USA
3 shared publicationsAnita P. Price
Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY, United States of America
3 shared publicationsAnita Price
Department of Radiology, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY
3 shared publications
Latest Publications
- Open Access
Three-Dimensional Imaging, Printing, and Augmented Reality in Surgical Oncology: A Descriptive Implementation Framework at a Comprehensive Cancer Center
Background: Three-dimensional (3D) visualization of radiological imaging has emerged as a valuable tool in surgical oncology, with applications spanning diagnostics, perioperative planning, intraoperative guidance, and patient communication. Despite its growing clinical relevance, integration into routine surgical workflows remains inconsistent and poorly standardized across specialties. Methods: We describe select cases illustrating a multispecialty feasibility and implementation experience evaluating the integration of 3D reconstruction, 3D printing, and augmented reality into surgical oncology workflows across a comprehensive cancer center. Describing cases and series of interest, we demonstrate how a structured implementation workflow was applied covering image acquisition, segmentation, volumetric rendering, and modality selection based on the specific clinical problem. A feasibility framework is proposed in terms of workflow integration, modality-to-problem fit, and clinical utility as described by the operating team. Results: Seven select case groups spanning pediatric, head and neck, urologic, gynecologic, and thoracic surgical oncology were included, with group sizes ranging from 1 to 14 patients. In 3 patients with hepatoblastoma, 3D printed anatomical models were successfully integrated into patient and family education consultations to convey tumor extent and the scope of planned resection. Segmentation-based visualization was implemented for preoperative planning in 2 patients with skull base malignancies, with the 3D workflow described as useful for operative planning by the operating team in both cases. Augmented reality (AR)-assisted 3D reconstruction was incorporated into the planning workflow for 3 patients undergoing robotic partial nephrectomy for complex renal tumors, facilitating review of vascular anatomy and assessment of the feasibility of nephron-sparing surgery. In 2 patients with suspected advanced ovarian cancer, volumetric rendering with AR was integrated into preoperative resectability planning. Among 14 patients undergoing chest wall tumor resection, patient-specific 3D printed ribcage replicas were used for preoperative implant preparation. In a separate cohort of 2 chest wall patients, AR visualization was used for spatial surgical planning. Conclusions: Across diverse oncologic contexts and surgical specialties, 3D reconstruction, printing, and augmented reality were successfully integrated into existing perioperative workflows, with each modality selected based on the specific clinical problem at hand. This experience describes a structured, modality-matched implementation framework that may serve as a practical starting point for institutions seeking to incorporate these technologies. Prospective, controlled studies are needed to establish independent clinical benefit. Broader adoption will require standardized selection criteria, prospective evaluation, and workflow adaptation for centers beyond high-volume academic institutions.
Open AccessThree-Dimensional Imaging, Printing, and Augmented Reality in Surgical Oncology: A Descriptive Implementation Framework at a Comprehensive Cancer Center
Background: Three-dimensional (3D) visualization of radiological imaging has emerged as a valuable tool in surgical oncology, with applications spanning diagnostics, perioperative planning, intraoperative guidance, and patient communication. Despite its growing clinical relevance, integration into routine surgical workflows remains inconsistent and poorly standardized across specialties. Methods: We describe select cases illustrating a multispecialty feasibility and implementation experience evaluating the integration of 3D reconstruction, 3D printing, and augmented reality into surgical oncology workflows across a comprehensive cancer center. Describing cases and series of interest, we demonstrate how a structured implementation workflow was applied covering image acquisition, segmentation, volumetric rendering, and modality selection based on the specific clinical problem. A feasibility framework is proposed in terms of workflow integration, modality-to-problem fit, and clinical utility as described by the operating team. Results: Seven select case groups spanning pediatric, head and neck, urologic, gynecologic, and thoracic surgical oncology were included, with group sizes ranging from 1 to 14 patients. In 3 patients with hepatoblastoma, 3D printed anatomical models were successfully integrated into patient and family education consultations to convey tumor extent and the scope of planned resection. Segmentation-based visualization was implemented for preoperative planning in 2 patients with skull base malignancies, with the 3D workflow described as useful for operative planning by the operating team in both cases. Augmented reality (AR)-assisted 3D reconstruction was incorporated into the planning workflow for 3 patients undergoing robotic partial nephrectomy for complex renal tumors, facilitating review of vascular anatomy and assessment of the feasibility of nephron-sparing surgery. In 2 patients with suspected advanced ovarian cancer, volumetric rendering with AR was integrated into preoperative resectability planning. Among 14 patients undergoing chest wall tumor resection, patient-specific 3D printed ribcage replicas were used for preoperative implant preparation. In a separate cohort of 2 chest wall patients, AR visualization was used for spatial surgical planning. Conclusions: Across diverse oncologic contexts and surgical specialties, 3D reconstruction, printing, and augmented reality were successfully integrated into existing perioperative workflows, with each modality selected based on the specific clinical problem at hand. This experience describes a structured, modality-matched implementation framework that may serve as a practical starting point for institutions seeking to incorporate these technologies. Prospective, controlled studies are needed to establish independent clinical benefit. Broader adoption will require standardized selection criteria, prospective evaluation, and workflow adaptation for centers beyond high-volume academic institutions.
- 5 November 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
18F-mFBG PET Detects Neuroblastoma Recurrence Prior to 123I-mIBG SPECT
Background: A high-risk stage M neuroblastoma patient suspected of residual disease in a T3-4 paraspinal soft tissue mass had no evidence of disease on MRI or 123 I- m IBG SPECT/CT. Observations: 18 F- m FBG PET/CT performed in a clinical trial showed abnormalities in the upper and lower thoracic spine, lumbar spine, and pelvis. Two months later, the MRI was unchanged, and 123 I- m IBG SPECT/CT showed only an equivocal upper thoracic spine focus. 123 I- m IBG SPECT/CT and MRI at 4 months post- 18 F- m FBG showed positive findings in the thoracic spine consistent with neuroblastoma. Conclusions: Follow-up confirmed that 18 F- m FBG PET/CT identified neuroblastoma at least 2 months prior to 123 I- m IBG and MRI.
- 5 November 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
18F-mFBG PET Detects Neuroblastoma Recurrence Prior to 123I-mIBG SPECT
Background: A high-risk stage M neuroblastoma patient suspected of residual disease in a T3-4 paraspinal soft tissue mass had no evidence of disease on MRI or 123 I- m IBG SPECT/CT. Observations: 18 F- m FBG PET/CT performed in a clinical trial showed abnormalities in the upper and lower thoracic spine, lumbar spine, and pelvis. Two months later, the MRI was unchanged, and 123 I- m IBG SPECT/CT showed only an equivocal upper thoracic spine focus. 123 I- m IBG SPECT/CT and MRI at 4 months post- 18 F- m FBG showed positive findings in the thoracic spine consistent with neuroblastoma. Conclusions: Follow-up confirmed that 18 F- m FBG PET/CT identified neuroblastoma at least 2 months prior to 123 I- m IBG and MRI.
- Open Access
- 17 September 2026
- Published by MDPI AG in Preprints.org
Three-Dimensional Imaging, Printing, and Mixed Reality in Surgical Oncology: A Feasibility and Implementation Framework at a Comprehensive Cancer Center
Background: Three-dimensional (3D) visualization of radiological imaging has emerged as a valuable tool in surgical oncology, with applications spanning diagnostics, perioperative planning, intraoperative guidance, and patient communication. Despite the growing clinical relevance of these technologies, integration into routine surgical workflows remains inconsistent and poorly standardized across specialties. Methods: We describe a multispecialty feasibility and implementation experience evaluating the integration of 3D reconstruction, 3D printing, and augmented reality into surgical oncology workflows at a comprehensive cancer center. For each case group, a structured implementation workflow was applied covering image acquisition, segmentation, volumetric rendering, and modality selection based on the specific clinical problem. Feasibility was assessed in terms of workflow integration, modality-to-problem fit, and clinical utility as described by the operating team. Results: We identified seven case groups spanning pediatric, head and neck, urologic, gynecologic, and thoracic surgical oncology (range, 1–16 patients/group). In hepatoblastoma cases, 3D-printed anatomical models were successfully integrated into patient and family education consultations to convey tumor extent and the scope of planned resection. Segmentation-based visualization was implemented for preoperative planning in two patients with skull-based malignancies; the surgical team described the 3D workflow as useful for operative planning. Augmented reality (AR)-assisted 3D reconstruction was incorporated into the planning workflow for three patients undergoing robotic partial nephrectomy for complex renal tumors, facilitating review of the vascular anatomy and assessment of whether nephron-sparing surgery was feasible. In two patients with suspected advanced ovarian cancer, volumetric rendering with AR was integrated into preoperative resectability planning. Among 14 patients undergoing resection of chest wall tumor, patient-specific 3D-printed rib cage replicas were used for preoperative implant preparation. In two other patients with chest wall tumors, AR visualization was used for spatial surgical planning. Conclusion: Across diverse oncologic contexts and surgical specialties, 3D reconstruction, printing, and AR were successfully integrated into existing perioperative workflows, with each modality selected based on the specific clinical problem at hand. This experience demonstrates the feasibility of a structured, modality-matched implementation framework that can serve as a practical starting point for institutions seeking to incorporate these technologies into surgical oncology practice. Broader adoption will require standardized selection criteria, prospective evaluation, and workflow adaptation for centers beyond high-volume academic institutions.
- 17 September 2026
- Published by MDPI AG in Preprints.org
Open AccessThree-Dimensional Imaging, Printing, and Mixed Reality in Surgical Oncology: A Feasibility and Implementation Framework at a Comprehensive Cancer Center
Background: Three-dimensional (3D) visualization of radiological imaging has emerged as a valuable tool in surgical oncology, with applications spanning diagnostics, perioperative planning, intraoperative guidance, and patient communication. Despite the growing clinical relevance of these technologies, integration into routine surgical workflows remains inconsistent and poorly standardized across specialties. Methods: We describe a multispecialty feasibility and implementation experience evaluating the integration of 3D reconstruction, 3D printing, and augmented reality into surgical oncology workflows at a comprehensive cancer center. For each case group, a structured implementation workflow was applied covering image acquisition, segmentation, volumetric rendering, and modality selection based on the specific clinical problem. Feasibility was assessed in terms of workflow integration, modality-to-problem fit, and clinical utility as described by the operating team. Results: We identified seven case groups spanning pediatric, head and neck, urologic, gynecologic, and thoracic surgical oncology (range, 1–16 patients/group). In hepatoblastoma cases, 3D-printed anatomical models were successfully integrated into patient and family education consultations to convey tumor extent and the scope of planned resection. Segmentation-based visualization was implemented for preoperative planning in two patients with skull-based malignancies; the surgical team described the 3D workflow as useful for operative planning. Augmented reality (AR)-assisted 3D reconstruction was incorporated into the planning workflow for three patients undergoing robotic partial nephrectomy for complex renal tumors, facilitating review of the vascular anatomy and assessment of whether nephron-sparing surgery was feasible. In two patients with suspected advanced ovarian cancer, volumetric rendering with AR was integrated into preoperative resectability planning. Among 14 patients undergoing resection of chest wall tumor, patient-specific 3D-printed rib cage replicas were used for preoperative implant preparation. In two other patients with chest wall tumors, AR visualization was used for spatial surgical planning. Conclusion: Across diverse oncologic contexts and surgical specialties, 3D reconstruction, printing, and AR were successfully integrated into existing perioperative workflows, with each modality selected based on the specific clinical problem at hand. This experience demonstrates the feasibility of a structured, modality-matched implementation framework that can serve as a practical starting point for institutions seeking to incorporate these technologies into surgical oncology practice. Broader adoption will require standardized selection criteria, prospective evaluation, and workflow adaptation for centers beyond high-volume academic institutions.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (2)
Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High-Dose Alkylator–Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
PURPOSE: Irinotecan and temozolomide (iT) have antitumor activity in relapsed Ewing sarcoma (ES). The purpose of this phase II trial was to evaluate whether iT added to an alkylator-intensified five-drug regimen (Ewing Family of Tumors [EFT]) improved the 4-year event free survival (EFS) for patients with newly diagnosed localized ES. METHODS: Patients with localized ES received six cycles of iT consolidation following completion of 21 weeks of EFT chemotherapy; patients with metastatic disease received 10 intercalated cycles of iT during EFT. The primary end point was 4-year EFS for patients with localized disease, with 85% and 70% of patients without events deemed promising and not promising, respectively. Secondary end points included EFS for metastatic patients, overall survival (OS), toxicity, and exploratory circulating tumor DNA analyses. RESULTS: Eighty-three patients were enrolled (46 localized, 37 metastatic; median age 16 years). The 4-year EFS for patients with localized disease was 76% (95% CI, 64% to 90%), which did not exceed the predefined threshold for unpromising efficacy. Among patients with metastatic disease, 4-year EFS was 56% (95% CI, 37% to 84%) for those with lung-only metastases and 43% (95% CI, 25% to 74%) for those with extrapulmonary metastases. Febrile neutropenia occurred in 96% of patients, most frequently following alkylator-containing cycles. Secondary malignancies developed in four patients. No unexpected toxicities were observed. CONCLUSION: The addition of iT to high-dose, alkylator-based up-front chemotherapy did not exceed the historical EFS benchmark in patients with radiographically localized ES.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (2)
Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High-Dose Alkylator–Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
PURPOSE: Irinotecan and temozolomide (iT) have antitumor activity in relapsed Ewing sarcoma (ES). The purpose of this phase II trial was to evaluate whether iT added to an alkylator-intensified five-drug regimen (Ewing Family of Tumors [EFT]) improved the 4-year event free survival (EFS) for patients with newly diagnosed localized ES. METHODS: Patients with localized ES received six cycles of iT consolidation following completion of 21 weeks of EFT chemotherapy; patients with metastatic disease received 10 intercalated cycles of iT during EFT. The primary end point was 4-year EFS for patients with localized disease, with 85% and 70% of patients without events deemed promising and not promising, respectively. Secondary end points included EFS for metastatic patients, overall survival (OS), toxicity, and exploratory circulating tumor DNA analyses. RESULTS: Eighty-three patients were enrolled (46 localized, 37 metastatic; median age 16 years). The 4-year EFS for patients with localized disease was 76% (95% CI, 64% to 90%), which did not exceed the predefined threshold for unpromising efficacy. Among patients with metastatic disease, 4-year EFS was 56% (95% CI, 37% to 84%) for those with lung-only metastases and 43% (95% CI, 25% to 74%) for those with extrapulmonary metastases. Febrile neutropenia occurred in 96% of patients, most frequently following alkylator-containing cycles. Secondary malignancies developed in four patients. No unexpected toxicities were observed. CONCLUSION: The addition of iT to high-dose, alkylator-based up-front chemotherapy did not exceed the historical EFS benchmark in patients with radiographically localized ES.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (1)
Trastuzumab Deruxtecan Is Active in Desmoplastic Small Round Cell Tumor
PURPOSE: Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma which remains almost universally fatal despite multimodality therapy. Human epidermal growth factor receptor 2 (HER2) has been identified as a potential therapeutic target prompting HER2-specific investigations and subsequent off-label treatment with fam-trastuzumab deruxtecan (T-DXd) in our DSRCT clinical cohort. METHODS: Fifty-two and 61 DSRCT patient samples were analyzed by immunohistochemical (IHC) assays and RNAseq, respectively. In addition, 19 patients at a single institution with DSRCT in need of therapy underwent IHC testing and RNAseq when feasible and received off-label T-DXd (monotherapy [n = 14], alternating with another agent [n = 2], concomitantly in combination [n = 2]; measurable disease [n = 17], adjuvant setting [n = 2]). RESULTS: HER2 expression levels by RNAseq were analyzed in the context of 346 patients with solid tumor and 23 histologies, with DSRCT having the third highest HER2 expression level overall and a median transcripts per million (TPM) expression level of 41.8 (range, 6.3-116.3). While TMA IHC analyses noted minimal HER2 IHC positivity using 4B5, IHC with clones 29D8 and CB11 uncovered 8.7- to 12.7-fold more HER2 reactivity, respectively. All 17 patients with measurable disease experienced clinical benefit (stable disease or partial response [PR]) with minimal toxicity. In addition, 9 of 17 patients achieved a RECIST PR (53% overall response rate). The response rate did not correlate with available IHC or RNAseq data, and some patients with no membranous IHC expression achieved PR. CONCLUSION: These data show that T-DXd is active in DSRCT and support the planned biomarker-agnostic formal clinical trial with the Children's Oncology Group.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (1)
Trastuzumab Deruxtecan Is Active in Desmoplastic Small Round Cell Tumor
PURPOSE: Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma which remains almost universally fatal despite multimodality therapy. Human epidermal growth factor receptor 2 (HER2) has been identified as a potential therapeutic target prompting HER2-specific investigations and subsequent off-label treatment with fam-trastuzumab deruxtecan (T-DXd) in our DSRCT clinical cohort. METHODS: Fifty-two and 61 DSRCT patient samples were analyzed by immunohistochemical (IHC) assays and RNAseq, respectively. In addition, 19 patients at a single institution with DSRCT in need of therapy underwent IHC testing and RNAseq when feasible and received off-label T-DXd (monotherapy [n = 14], alternating with another agent [n = 2], concomitantly in combination [n = 2]; measurable disease [n = 17], adjuvant setting [n = 2]). RESULTS: HER2 expression levels by RNAseq were analyzed in the context of 346 patients with solid tumor and 23 histologies, with DSRCT having the third highest HER2 expression level overall and a median transcripts per million (TPM) expression level of 41.8 (range, 6.3-116.3). While TMA IHC analyses noted minimal HER2 IHC positivity using 4B5, IHC with clones 29D8 and CB11 uncovered 8.7- to 12.7-fold more HER2 reactivity, respectively. All 17 patients with measurable disease experienced clinical benefit (stable disease or partial response [PR]) with minimal toxicity. In addition, 9 of 17 patients achieved a RECIST PR (53% overall response rate). The response rate did not correlate with available IHC or RNAseq data, and some patients with no membranous IHC expression achieved PR. CONCLUSION: These data show that T-DXd is active in DSRCT and support the planned biomarker-agnostic formal clinical trial with the Children's Oncology Group.
- Open Access
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2) , e2400095
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results
PURPOSE: We hypothesized that ACR-368 (prexasertib) would be active in desmoplastic small round cell tumor (DSRCT) because of favorable responses in preclinical models. METHODS: Preclinical work identified ACR-368 activity in DSRCT, and a phase I/II trial of ACR-368 and irinotecan in patients 12 months and older with relapsed/refractory DSRCT was conducted. The primary objectives were determination of recommended phase II dose (RP2D) and best overall response rate (ORR) at the RP2D in DSRCT, with ≥3 of 16 responses considered promising. RESULTS: Preclinical data confirmed ACR-368 as potentially therapeutic in DSRCT, and 19 patients were enrolled in a subsequent clinical trial. Treatment was well tolerated, and cytopenias were managed using growth factors. Fifteen of 19 patients, including five of six achieving PR, had previously received irinotecan. The estimated ORR at the RP2D was 23% (lower boundary one-sided 90% CI, 9%), exceeding the unpromising rate of 5%. In addition, three patients with DSRCT had a PR at doses other than the RP2D, bringing the ORR for all doses (n = 19) to 32% (90% CI, 15% to 53%). The median overall survival was 19 months (95% CI, 13 to 36). CONCLUSION: The RP2D of ACR-368 with irinotecan by age group is ACR-368 105 or 150 mg/m 2 once on day 1 (>21 years or ≤21 years, respectively) and irinotecan 15 mg/m 2 once daily for 5 days in 21-day cycles for both groups. The study met its primary objective to consider ACR-368 and irinotecan promising in DSRCT and, to our knowledge, is the first incorporating a targeted therapy to achieve this magnitude of response.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2) , e2400095
Open AccessACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results
PURPOSE: We hypothesized that ACR-368 (prexasertib) would be active in desmoplastic small round cell tumor (DSRCT) because of favorable responses in preclinical models. METHODS: Preclinical work identified ACR-368 activity in DSRCT, and a phase I/II trial of ACR-368 and irinotecan in patients 12 months and older with relapsed/refractory DSRCT was conducted. The primary objectives were determination of recommended phase II dose (RP2D) and best overall response rate (ORR) at the RP2D in DSRCT, with ≥3 of 16 responses considered promising. RESULTS: Preclinical data confirmed ACR-368 as potentially therapeutic in DSRCT, and 19 patients were enrolled in a subsequent clinical trial. Treatment was well tolerated, and cytopenias were managed using growth factors. Fifteen of 19 patients, including five of six achieving PR, had previously received irinotecan. The estimated ORR at the RP2D was 23% (lower boundary one-sided 90% CI, 9%), exceeding the unpromising rate of 5%. In addition, three patients with DSRCT had a PR at doses other than the RP2D, bringing the ORR for all doses (n = 19) to 32% (90% CI, 15% to 53%). The median overall survival was 19 months (95% CI, 13 to 36). CONCLUSION: The RP2D of ACR-368 with irinotecan by age group is ACR-368 105 or 150 mg/m 2 once on day 1 (>21 years or ≤21 years, respectively) and irinotecan 15 mg/m 2 once daily for 5 days in 21-day cycles for both groups. The study met its primary objective to consider ACR-368 and irinotecan promising in DSRCT and, to our knowledge, is the first incorporating a targeted therapy to achieve this magnitude of response.
- 1 October 2023
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 221 (4) , 538
Editorial Comment: A Call for Pediatric Radiologists to Explore Dual-Energy CT
- 1 October 2023
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 221 (4) , 538
Editorial Comment: A Call for Pediatric Radiologists to Explore Dual-Energy CT
- 6 September 2023
- Published by Springer Nature in Skeletal Radiology
- Vol. 53 (4) , 817-820
Osteopetrorickets: two contradictory patterns—one unifying diagnosis
A 5-month-old infant with bone findings on x-ray presented an apparent contradiction including findings of both diffusely dense bones and rickets in the context of a history and laboratory investigation that suggested leukemia. Next generation gene panel sequencing revealed a TCIRG1 mutation which is consistent with autosomal recessive osteopetrosis. The paradoxical x-ray findings underscore a recently elucidated mechanism for the pathogenesis of a TCIRG mutation. This case highlights the importance of recognizing this radiographic, seeming contradictory, association in the context of a confusing clinical presentation. Failure to recognize this pattern promptly may lead to a delay in diagnosis, thus potentially permanent organ failure.
- 6 September 2023
- Published by Springer Nature in Skeletal Radiology
- Vol. 53 (4) , 817-820
Osteopetrorickets: two contradictory patterns—one unifying diagnosis
A 5-month-old infant with bone findings on x-ray presented an apparent contradiction including findings of both diffusely dense bones and rickets in the context of a history and laboratory investigation that suggested leukemia. Next generation gene panel sequencing revealed a TCIRG1 mutation which is consistent with autosomal recessive osteopetrosis. The paradoxical x-ray findings underscore a recently elucidated mechanism for the pathogenesis of a TCIRG mutation. This case highlights the importance of recognizing this radiographic, seeming contradictory, association in the context of a confusing clinical presentation. Failure to recognize this pattern promptly may lead to a delay in diagnosis, thus potentially permanent organ failure.
- 9 May 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (9) , e30410
Slipped capital femoral epiphyses: A major on‐target adverse event associated with FGFR tyrosine kinase inhibitors in pediatric patients
Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors (TKIs) are increasingly being used off label in pediatrics. Long‐term safety data are limited, and serious toxicities unique to pediatrics may emerge. In a retrospective analysis of patients less than 18 years of age with recurrent/refractory FGFR altered gliomas treated with FGFR TKIs at MSKCC (n = 7), we observed slipped capital femoral epiphyses in three of seven patients along with increased linear growth velocity. Clinicians should closely monitor bone health and have a low index of suspicion for serious orthopedic complications including slipped capital femoral epiphyses and inform patients of related risks as part of consent when treating with FGFR TKIs.
- 9 May 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (9) , e30410
Slipped capital femoral epiphyses: A major on‐target adverse event associated with FGFR tyrosine kinase inhibitors in pediatric patients
Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors (TKIs) are increasingly being used off label in pediatrics. Long‐term safety data are limited, and serious toxicities unique to pediatrics may emerge. In a retrospective analysis of patients less than 18 years of age with recurrent/refractory FGFR altered gliomas treated with FGFR TKIs at MSKCC (n = 7), we observed slipped capital femoral epiphyses in three of seven patients along with increased linear growth velocity. Clinicians should closely monitor bone health and have a low index of suspicion for serious orthopedic complications including slipped capital femoral epiphyses and inform patients of related risks as part of consent when treating with FGFR TKIs.
- Open Access
A Novel Low-Rank Tensor Method for Undersampling Artifact Removal in Respiratory Motion-Resolved Multi-Echo 3D Cones MRI
We propose a novel low-rank tensor method for respiratory motion-resolved multi-echo image reconstruction. The key idea is to construct a 3-way image tensor (space $\times$ echo $\times$ motion state) from the conventional gridding reconstruction of highly undersampled multi-echo k-space raw data, and exploit low-rank tensor structure to separate it from undersampling artifacts. Healthy volunteers and patients with iron overload were recruited and imaged on a 3T clinical MRI system for this study. Results show that our proposed method Successfully reduced severe undersampling artifacts in respiratory motion-state resolved complex source images, as well as subsequent R2* and quantitative susceptibility mapping (QSM). Compared to conventional respiratory motion-resolved compressed sensing (CS) image reconstruction, the proposed method had a reconstruction time at least three times faster, accounting for signal evolution along the echo dimension in the multi-echo data.Open AccessA Novel Low-Rank Tensor Method for Undersampling Artifact Removal in Respiratory Motion-Resolved Multi-Echo 3D Cones MRI
We propose a novel low-rank tensor method for respiratory motion-resolved multi-echo image reconstruction. The key idea is to construct a 3-way image tensor (space $\times$ echo $\times$ motion state) from the conventional gridding reconstruction of highly undersampled multi-echo k-space raw data, and exploit low-rank tensor structure to separate it from undersampling artifacts. Healthy volunteers and patients with iron overload were recruited and imaged on a 3T clinical MRI system for this study. Results show that our proposed method Successfully reduced severe undersampling artifacts in respiratory motion-state resolved complex source images, as well as subsequent R2* and quantitative susceptibility mapping (QSM). Compared to conventional respiratory motion-resolved compressed sensing (CS) image reconstruction, the proposed method had a reconstruction time at least three times faster, accounting for signal evolution along the echo dimension in the multi-echo data.